Active, not recruitingPhase 3NCT04370054
Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults
Studying Hemophilia A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy(biological)
- Enrollment
- 77 enrolled
- Eligibility
- 18-64 years · MALE
- Timeline
- 2020 – 2028
Study locations (30)
- NOW Physical Therapy, Mountain View, California, United States
- Clinical and Translational Research Unit (CTRU), Palo Alto, California, United States
- Lucile Packard Childrens Hospital, Palo Alto, California, United States
- Imaging Clinic at Stanford Medicine Outpatient Center in Redwood City, Redwood City, California, United States
- UCSF IDS Pharmacy, San Francisco, California, United States
- University of California, San Francisco - Clinical Research Center, San Francisco, California, United States
- University of California, San Francisco - Moffitt/Long Inpatient Hematology, San Francisco, California, United States
- University of California, San Francisco - Outpatient Hematology Clinic, San Francisco, California, United States
- Stanford Health Care, Stanford, California, United States
- Washington Institute for Coagulation, Seattle, Washington, United States
- University of Washington Medical Center - Translational Research Unit (TRU), Seattle, Washington, United States
- The Alfred Hospital, Melbourne, Victoria, Australia
- Centro de Hematologia e Hemoterapia de Campinas - Hemocentro UNICAMP, Campinas, São Paulo, Brazil
- McMaster University Medical Centre - Hamilton Health Sciences, Hamilton, Ontario, Canada
- Juravinski Hospital - Hamilton Health Sciences, Hamilton, Ontario, Canada
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04370054 on ClinicalTrials.govOther trials for Hemophilia A
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05936580Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for SurgeryOctapharma
- ACTIVE NOT RECRUITINGNCT07161687A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.Pfizer
- RECRUITINGPHASE4NCT06864975Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)Runhui WU
- RECRUITINGPHASE1NCT06579144Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ASwedish Orphan Biovitrum
- RECRUITINGPHASE3NCT06738485Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCSL Behring
- RECRUITINGNCT06684314A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanSanofi
- RECRUITINGNCT07414511Hemophilia A Research ProgramUniversity of Washington
- RECRUITINGEARLY PHASE1NCT06345833Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded StudyUniversity of Minnesota